Literature DB >> 16201271

Effects of hypoxia on expression of P-gp and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line.

Shu Xia1, Shiying Yu, Xianglin Yuan.   

Abstract

To study the effects of hypoxia-on the expression of P-gp and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line, and to explore the probable mechanism of hypoxia in tumor cell of MDR. The expression of hypoxia inducible factor-1 alpha, P-gp and mutltidrug resistance protein was immunohistochemically detected by culturing human lung adenocarcinoma A549 cell under hypoxia (2 % O2) for 24 h. After interaction with adriamycin or cisplatin under hypoxia (2 % O2) for 24 h, the cell survival rate was detected by MTT. Our results showed that the expression of hypoxia inducible factor-1 alpha, P-gp and mutltidrug resistance protein under hypoxia were higher than the expression under normoxia, and correlations between the expression of HIF-1alpha and P-gp or multidrug resistance-associated protein was observed (P< 0.05). The resistance of adriamycin of A549 cell was enhanced under hypoxia. It is concluded that the resistance of tumor chemotherapy is enhanced in hypoxia. The expression of HIF-1alpha is obviously correlated with the expression of P-gp and mutltidrug resistance protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16201271     DOI: 10.1007/bf02828142

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  5 in total

1.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension.

Authors:  B H Jiang; G L Semenza; C Bauer; H H Marti
Journal:  Am J Physiol       Date:  1996-10

2.  Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells.

Authors:  M Wartenberg; F Dönmez; F C Ling; H Acker; J Hescheler; H Sauer
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

3.  Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species.

Authors:  Maria Wartenberg; Frederike C Ling; Markus Müschen; Florian Klein; Helmut Acker; Max Gassmann; Kerstin Petrat; Volker Pütz; Jürgen Hescheler; Heinrich Sauer
Journal:  FASEB J       Date:  2003-01-02       Impact factor: 5.191

4.  Tubulogenesis in Drosophila: a requirement for the trachealess gene product.

Authors:  D D Isaac; D J Andrew
Journal:  Genes Dev       Date:  1996-01-01       Impact factor: 11.361

5.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

Authors:  Katrina M Comerford; Timothy J Wallace; Jörn Karhausen; Nancy A Louis; Michael C Montalto; Sean P Colgan
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

  5 in total
  5 in total

Review 1.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

Review 2.  Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer.

Authors:  Tobeka Naki; Blessing A Aderibigbe
Journal:  Pharmaceutics       Date:  2022-05-13       Impact factor: 6.525

3.  Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.

Authors:  Blenda Chi Kwan Wong; Hongqi Zhang; Ling Qin; Hubiao Chen; Chen Fang; Aiping Lu; Zhijun Yang
Journal:  Drug Des Devel Ther       Date:  2014-07-22       Impact factor: 4.162

Review 4.  [Advances in hypoxia microenvironment and chemotherapy-resistant of lung cancer].

Authors:  Yang Guo; Milu Wu; Junhui Zhao; Yuying Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-03

Review 5.  Role of hypoxia in cancer therapy by regulating the tumor microenvironment.

Authors:  Xinming Jing; Fengming Yang; Chuchu Shao; Ke Wei; Mengyan Xie; Hua Shen; Yongqian Shu
Journal:  Mol Cancer       Date:  2019-11-11       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.